Lenacapavir is an injectable drug administered twice a year, unlike current HIV prevention (PrEP) and antiretroviral (ARV) ...

According to health officials, at the civil hospital’s anti-retroviral therapy (ART) centre, nearly 100 people are screened ...

Lenacapavir represents a fundamental shift from traditional HIV prevention strategies, which have largely relied on daily ...

A smartphone-based tool designed to monitor real-time health risk behaviours among high-risk HIV populations has demonstrated high usability and feasibility, according to a new study conducted among ...

A SMARTPHONE app for HIV risk tracking showed high usability and strong daily compliance among MSM with HIV. Smartphone App ...

Lenacapavir: a game changer in SA’s fight against HIV While Health Minister, Dr Aaron Motsoaledi, is still to announce the date for the launch of the game changing HIV prevention medication ...

Advances in hereditary angioedema attack prophylaxis have provided more options for patients than ever before, with multiple ...

The FDA accepted an NDA for a bictegravir and lenacapavir single-tablet regimen for adults with HIV-1 who have achieved virologic suppression.

However, most patients report preferring LAI-ART administered monthly or once every 2 months vs daily oral ART.

Barriers GLP-1 adherence systems face include cost, side effects, and care models; health systems use structured ...

Antiretroviral therapy regimen switching occurs frequently among virologically suppressed individuals with HIV to optimize clinical treatment.

The FCT has launched LenPrEP, a free long-acting HIV prevention injection. This twice-a-year medication is now available to ...